- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 22.10. | Sanofi's $1.7B rare disease bet beats CSL's Zemaira in phase 2 face-off | ||
| 22.10. | Ipsen writes check worth up to €1B to acquire next-gen cancer biotech | ||
| 22.10. | Takeda pays Innovent $1.2B upfront for rights to 2 cancer candidates | ||
| 22.10. | Terns mothballs obesity program after phase 2 data fall short | ||
| 21.10. | 'We need to pick a lane': Lilly oncology president weighs in on FDA cancer drug policies | ||
| 21.10. | GSK unveils positive pivotal data for Spero's once-rejected oral antibiotic | ||
| 21.10. | Neuphoria nixes social anxiety program and starts strategic review after phase 3 flop | ||
| 21.10. | Galapagos to wind down cell therapy unit, threatening 365 jobs and 5 facilities | ||
| 20.10. | US private equity shows signs of recovery, positions year to end 'on a high note': PitchBook | ||
| 20.10. | BioNTech fades out further work with cancer vaccine prospect in late-stage melanoma setting | ||
| 20.10. | How to invest in America? Vaccinate: BIO rolls out awareness campaign amid rising misinformation | ||
| 20.10. | ESMO: Daiichi, Merck power ovarian cancer ADC toward pivotal test after passing phase 2 | ||
| 20.10. | Roche claws its way toward FDA as phase 3 eye disease trials yield mixed results | ||
| 18.10. | ESMO: AstraZeneca believes latest data 'validate' going it alone on next-gen ADCs | ||
| 17.10. | Xoma and Lava buyout cools with lower cash offer and closing conditions | ||
| 17.10. | ESMO: Evaxion hopes cancer vax data attracts partner after cash crunch forces smaller ph. 2 trial | ||
| 17.10. | ESMO: Pfizer sees year-long weight gain in cancer patients with wasting condition | ||
| 17.10. | Licensing galore: Roche ties up with Hansoh on ADCs as Rani rounds out week with Chugai pact | ||
| 17.10. | Astellas walks away from gene therapy pact with Taysha before pivotal trial launch | ||
| 17.10. | I-Mab undergoes makeover, with new name, strategy, asset and Hong Kong IPO plans | ||
| 17.10. | ESMO: BMS looks to 'stay ahead of the competition' with ADC's 55% response rate in early-stage trial | ||
| 17.10. | Unpacking the FDA transparency push on CRLs | ||
| 17.10. | Kezar plans layoffs after FDA cancels meeting to discuss next trial | ||
| 17.10. | FDA names nine first recipients of 1-to-2 month priority review vouchers | ||
| 16.10. | Kite puts $1.6B on the line to pair up with China's Pregene for another in vivo CAR-T deal |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .